Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Innate Immunity, Oncology, and Infectious Disease Development.
Biological Context & Key Mutations
TLR8 (CD288) is an endosomal receptor of the Toll-like receptor family that recognizes single-stranded RNA and activates NF-κB signaling via the MyD88 adaptor. Key functional domains include the LRRCT (leucine-rich repeat C-terminal) and TIR (Toll/interleukin-1 receptor) domains. Clinically relevant mutations include:
- dbSNP rs5744077 – a missense variant in the TIR domain (UniProt VAR_024667).
- IMD98 gain-of-function variants – two mutations (UniProt VAR_087088 and VAR_087089) that enhance NF-κB activation and are associated with immunodeficiency.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TLR8/CD288 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TLR8/CD288 ECD-LRR Fusion Protein & ECD-Fc Variants. High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified, HEK293 expressed (native glycosylation). Mutant protein also available. | View TLR8 Products |
| Gene Delivery | TLR8 Full-Length ORF Lentivirus (titer >1×10⁸ TU/ml). For stable cell line construction preserving endosomal trafficking and native conformation. | View TLR8 Products |
| Benchmark Ab | Anti-TLR8 Neutralizing Reference Antibody (clone details on request). Recombinant positive control for specificity benchmarking and antagonist screening. | View TLR8 Products |
| Validator | TLR8 siRNA Set – for knockdown verification and specificity controls in reporter assays. | View TLR8 Products |
| Related Target A | TLR7 – synergistic endosomal receptor; dual TLR7/8 agonism is a key clinical strategy. | View TLR7 Products |
| Related Target B | TLR9 – endosomal pathway partner for combinatorial innate immune activation. | View TLR9 Products |
| Related Target C | MyD88 – downstream adaptor essential for TLR8 signal transduction validation. | View MyD88 Products |
| Related Target D | IRF7 – downstream transcription factor for efficacy readout in reporter cell lines. | View IRF7 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Human/Cyno/Mouse Ortholog Screening | Human, Cynomolgus, and Mouse TLR8 ECD proteins available (>95% purity, mass spec verified). Note: mouse TLR8 does not respond to imidazoquinolines. |
| TLR7/8/9 Selectivity Screening | Homolog panel (TLR7, TLR8, TLR9) proteins strictly verified by mass spectrometry. |
| Endosomal Localization & Signaling | Full-length TLR8 lentivirus for stable cell lines preserving native endosomal trafficking and NF-κB reporter activity. |
| Lack of Controls & False Positives | Validated siRNA and benchmark neutralizing antibody included for knockdown and blocking controls. |
| Assay Format Flexibility (SPR/BLI/ELISA) | High-purity ECD-Fc and ECD-LRR proteins suitable for binding kinetic assays. |
Live TLR8/CD288 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TLR8 therapeutics is intensifying, with the landscape bifurcating between oncology agonists (activating innate immunity in the tumor microenvironment) and autoimmune antagonists (suppressing hyperactive TLR8 signaling in SLE and RA). First-generation small-molecule agonists (e.g., Motolimod) faced systemic toxicity challenges, driving innovation toward tumor-targeted delivery systems such as:
- Immune-Stimulating Antibody Conjugates (ISACs) – conjugating TLR8 agonists to tumor-targeting antibodies (e.g., HER2, CEA) to restrict activation to the tumor microenvironment.
- Liver-targeted prodrugs for HBV therapy.
- Dual TLR7/8 modulators aiming to balance efficacy and safety.
Major players include Gilead (HBV/HIV cure programs), Bristol Myers Squibb (ADC BMS-986179), Nektar (NKTR-262), and Tallac Therapeutics (ISAC platform). As the field pivots from systemic administration to localized activation, demand for high-fidelity species-specific reagents has intensified—particularly given functional divergence between human and murine TLR8.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Gilead, Bristol Myers Squibb, Nimbus Therapeutics, Nektar (NKTR-262), VentiRx, Novartis | Hepatitis B, Solid Tumors (HCC, HNSCC, Melanoma) | Cell-based NF-κB reporter assay (full-length TLR8 lentivirus); species-specific activation assays (human vs cyno TLR8 proteins). |
| Dual TLR7/8 Agonist | Multiple biotechs/pharma, Daiichi Sankyo, Takeda | Oncology, Viral Infections | Selectivity assay (TLR7 vs TLR8 vs TLR9 protein panel); cross-reactivity verification. |
| ISACs / ADCs | Tallac Therapeutics, Bolt Biotherapeutics, Bristol Myers Squibb (BMS-986179) | Solid Tumors (TNBC, Lung, Head & Neck) | Endosomal release & binding (high-purity ECD-Fc); internalization assays using TLR8 lentivirus. |
| Antagonist / Inverse Agonist | Biogen, Merck, early discovery biotechs | Autoimmune (SLE, Rheumatoid Arthritis) | Receptor blockade assay (sequence verified ECDs); neutralizing antibody benchmarks; MyD88 pathway inhibition. |